Galapagos (GLPG) Q3 2025 earnings summary

Executive summary

• Announced intention to wind down the cell therapy business after a failed spin-off and unsuccessful sale process, impacting up to 365 employees and leading to site closures in Europe, the U.S., and China, subject to works council consultations.

• Strategic focus shifts to transformative business development, leveraging a strong cash position and partnership with Gilead to pursue de-risked, value-creating opportunities in oncology and immunology.

• Leadership team and board refreshed with new executive appointments and expanded to support transformation and future growth.

• Focus on disciplined capital allocation and building a novel therapeutic pipeline, prioritizing small molecule and biologics programs.

Financial highlights

• Net loss from continuing operations was €463.0 million for the first nine months of 2025, compared to €20.4 million loss in the prior year, mainly due to a €204.8 million impairment on the cell therapy business and €135.5 million in restructuring costs.

• Total net revenues increased 6% year-over-year to €211.4 million, driven by €182.1 million from collaborations.

• R&D expenses rose 48% to €351.9 million, mainly due to severance, asset impairments, and early termination of collaborations.

• Cash, cash equivalents, and financial investments totaled €3.05 billion as of September 30, 2025, with expected year-end cash of €2.975–3.025 billion.

• Operating cash burn for the first nine months was €145.1 million.

Outlook and guidance

• Anticipates ending 2025 with €2.975–3.025 billion in cash and equivalents, excluding business development activities and currency fluctuations.

• Expects to be cash flow neutral to positive by end of 2026, assuming completion of the wind down and no major business development outlays.

• One-time restructuring cash costs related to the wind down are estimated at €150–200 million in 2026, with additional operating cash impacts of €100–125 million from Q4 2025 through 2026.

• Topline results from GLPG3667 Phase 3-enabling studies in SLE and dermatomyositis expected in early 2026.